UK markets open in 2 hours 23 minutes
NIKKEI 225
38,365.00 -40.66 (-0.11%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.18 -0.75 (-0.92%) GOLD FUTURES
2,292.90 -10.00 (-0.43%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
48,265.40 -2,708.35 (-5.31%)
Clinuvel Pharmaceuticals Limited (CLVLF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 12:37PM EDT
| Previous close | 9.99 |
| Open | 10.05 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 9.77 - 10.05 |
| 52-week range | 8.57 - 13.15 |
| Volume | |
| Avg. volume | 516 |
| Market cap | 494.762M |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | 26.39 |
| EPS (TTM) | 0.37 |
| Earnings date | N/A |
| Forward dividend & yield | 0.03 (0.32%) |
| Ex-dividend date | 05 Sept 2023 |
| 1y target est | N/A |
Simply Wall St.Is Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Clinuvel Pharmaceuticals' (ASX:CUV) stock is up by a considerable 8.7% over the past month. Since the market usually...
GlobeNewswirePhotomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years
- Simply Wall St.
Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 50% loss from investing in the stock three years ago
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Clinuvel Pharmaceuticals...
© 2024 Yahoo. All rights reserved.